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Abstract⎯Based on the active ingredient of the drug Ximedon (1,2-dihydro-4,6-dimethyl-1-N-(2-
hydroxyethyl)pyrimidone-2, referred below to as pyrimidine (I), novel derivatives containing biogenic acids:
succinic, L-ascorbic, para-aminobenzoic, nicotinic, and L-2-amino-4-(methylthio)butanoic (L-methi-
onine) acids have been synthesized. The parameters of acute toxicity (LD50) have been studied. The antitoxic
effect of the compounds upon the injury by the hepatotropic poison carbon tetrachloride has been examined
as the primary evaluation of their hepatoprotective properties. It has been found that, according to toxicolog-
ical safety, the compounds synthesized belong to classes III and IV (moderately and little toxic compounds).
The conjugates of pyrimidine (I) with ascorbic acid and methionine (LD50 more than 5400 mg/kg) are least
toxic. Pyrimidine (I) and its derivatives possess the antitoxic activity upon acute poisoning with carbon tet-
rachloride; the combined injection of carbon tetrachloride with pyrimidine (I) or its derivatives leads to an
increase in the survival of animals and the normalization of the integral functional parameters, weight and
body temperature, which decrease upon toxic injury. In addition, pyrimidine (I) and some of its derivatives
(conjugates with L-ascorbic, succinic, para-aminobenzoic, and nicotinic acids) decrease the weight coeffi-
cients of the liver and kidneys (the organ-to-body-weight ratio) and the activity of transaminases, the markers
of hepatic cytolysis, which increase upon toxic injury with carbon tetrachloride. The area of the pathological
injury of the liver by steatosis and necrosis decreases by the action of pyrimidine (I) and its novel derivatives
(conjugates with L-ascorbic, succinic, and nicotinic acids) two to three times. Advantages of pyrimidine (I)
and its novel derivatives over the hepatoprotective drug Thiotriazolin have been revealed.
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INTRODUCTION
According to the data of the World Health Organi-
zation, more than two billion people in the world suf-
fer from liver diseases. This situation requires an
increasingly frequent prescription of hepatoprotectors
whose main function is the prophylaxis and treatment
of liver cells for injuries induced by hepatotoxins. In
this connection, a search for hepatoprotectors is one
of the priority problems of national public health.
Pyrimidine derivatives attract attention as potential
hepatoprotectors owing to their capacity to stimulate
tissue regeneration. Among pyrimidine derivatives,
the drug oxymethyluracil (2-methyl-4-amino-6-oxy-
pyrimidine) has been found to exhibit hepatoprotec-
tive properties [1]. We have shown earlier that the
pyrimidine derivative 1,2-dihydro-4,6-dimethyl-1-N-
(2-hydroxyethyl-pyrimid-2-on (compound (I) in Fig. 1),
which is an active ingredient of the medicine Xime-
don, and its L-ascorbate (compound (III) in Fig. 1)
hold promise; they increase the adaptation reserves of
the organism under stress conditions of high physical
loads in the “forced swimming” test [2] and stimulate
the liver regeneration after toxic injury by carbon tet-
rachloride [3, 4]. In addition, it has been shown that
pyrimidine derivatives based on Ximedon possess a neu-
roprotective activity by beneficially affecting the regener-
ation of spinal cortex tissue after traumas [5, 6].
The aim of the present work was to study the hepa-
toprotective effect of novel pyrimidine derivatives of
the active ingredient (I) of Ximedon, its salt-like con-
jugates with biogenic acids: succinic, L-ascorbic,
para-aminobenzoic, nicotinic, and L-2-amino-4-
(methylthio)butanoic (L-methionine) acids (com-
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Abbreviations: LD50, a dose that causes the death of 50% of ani-
mals; ALT, alanine aminotransferase; AST, aspartate amino-
transferase.
